신우팜

비상장계속사업자

sinwoopharm co.

이형태

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

신우팜

Business Reg. No. 6078191034 · CEO 이형태

I.Investment Overview

Target신우팜 (6078191034)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명신우팜
영문명sinwoopharm co.
대표자이형태
사업자등록번호6078191034
법인등록번호1801110679142
설립일2009.09.01

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW1422021162.42022163.32023169.22024157.32025
영업이익100M KRW13.7202121.1202230.9202322202422.72025
순이익100M KRW6.8202114.2202217.8202314.4202417.22025
Item20252024202320222021
자산총계237.3억원226.4억원208.1억원211.8억원206.3억원
부채총계96.5억원102.7억원98.9억원120.4억원129.1억원
자본총계140.8억원123.7억원109.3억원91.4억원77.2억원
매출액157.3억원169.2억원163.3억원162.4억원142억원
영업이익22.7억원22억원30.9억원21.1억원13.7억원
순이익17.2억원14.4억원17.8억원14.2억원6.8억원

VI.Financial Ratios

FY2025 basis

14.42%

영업이익률

10.91%

순이익률

7.23%

ROA

12.18%

ROE

68.48%

부채비율

59.35%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

신우팜 투심보고서 | Alpha Lenz